Zenas BioPharma to host virtual R&D event on pipeline updates
Bitget2026/10/06 11:05Zenas BioPharma will host a virtual R&D event on Oct. 27, 2026, from 8:00 a.m. to 9:30 a.m. ET. Management will outline the R&D pipeline, with a focus on obexelimab in systemic lupus erythematosus. Updates will also cover development of ZB021, an oral IL-17AA/AF inhibitor. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610060705PRIMZONEFULLFEED9840230) on October 06, 2026, and is solely responsible for the information contained therein.
- Zenas BioPharma will host a virtual R&D event on Oct. 27, 2026, from 8:00 a.m. to 9:30 a.m. ET.
- Management will outline the R&D pipeline, with a focus on obexelimab in systemic lupus erythematosus.
- Updates will also cover development of ZB021, an oral IL-17AA/AF inhibitor.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The number of stablecoin holders on the Solana chain has surpassed 14 million.
Cathie Wood’s ARK Sells Bitcoin ETF, SpaceX and Robinhood Shares in Portfolio Shift
Analyst Gu Jingci: 10.10 Bitcoin/Ethereum Evening Trading Strategies and Market Analysis
Tekedia Capital flags signs global bond sell-off is losing momentum
Crypto prices
More
